Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors-Reference-Cited by-同舟云学术

Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors

Published:2021-04-21 Issue:13 Volume:27 Page:3620-3629
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:Clin Cancer Res

Author:

Curigliano Giuseppe^ORCID,Gelderblom Hans^ORCID,Mach Nicolas^ORCID,Doi Toshihiko^ORCID,Tai David,Forde Patrick M.,Sarantopoulos John,Bedard Philippe L.^ORCID,Lin Chia-Chi^ORCID,Hodi F. Stephen,Wilgenhof Sofie,Santoro Armando^ORCID,Sabatos-Peyton Catherine A.,Longmire Tyler A.,Xyrafas Alexandros,Sun Haiying,Gutzwiller Sabine,Manenti Luigi,Naing Aung^ORCID

Funder

Novartis Pharmaceuticals Corporation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 199 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immune checkpoint inhibitors rechallenge in non-small cell lung cancer: Current evidence and future directions;Cancer Letters;2024-11

2. Alterations in intratumoral and peripheral immune status in recurrent gliomas and their prognostic implications for patients underwent reoperation;International Immunopharmacology;2024-10

3. Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach;Nature Reviews Clinical Oncology;2024-09-04

4. Correction: Phase I/Ib Clinical Trial of Sabatolimab, an Anti–TIM-3 Antibody, Alone and in Combination with Spartalizumab, an Anti–PD-1 Antibody, in Advanced Solid Tumors;Clinical Cancer Research;2024-09-03

5. Regulatory T cells: masterminds of immune equilibrium and future therapeutic innovations;Frontiers in Immunology;2024-09-03